Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
fluticasone propionate, Quantity: 250 microgram/actuation; salmeterol xinafoate, Quantity: 72.5 microgram/actuation (Equivalent: salmeterol, Qty 50 microgram/actuation)
GlaxoSmithKline Australia Pty Ltd
fluticasone propionate,Salmeterol xinafoate
Inhalation, powder for
Excipient Ingredients: lactose monohydrate
Oral
60 dose, 28 dose (sample), 28 dose
(S4) Prescription Only Medicine
For the regular treatment of asthma, where the use of a combination product is appropriate. This may include:,*Patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids.,*Patients who are symptomatic on current inhaled corticosteroid therapy.,For the symptomatic treatment of patients with severe COPD (FEV1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. Pavtide is not indicated for the initiation of bronchodilator therapy in COPD.
Visual Identification: A two-tone purple, circular device in moulded plastic, approximately 8.5cm in diameter and approximately 3cm high, with a dose counter indicating 28 or 60 doses.; Container Type: Blister Pack; Container Life Time: 24 Months; Container Temperature: Store below 30 degrees Celsius
Licence status A
2014-05-07
PAVTIDE ACCUHALER P A V T I D E CONSUMER MEDICINE INFORMATION (CMI) SUMMARY The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. WHY AM I USING PAVTIDE ACCUHALER? PAVTIDE ACCUHALER contains the active ingredients fluticasone propionate and salmeterol xinafoate. PAVTIDE ACCUHALER is used to help with asthma and chronic obstructive pulmonary disease (COPD) in people who need regular treatment. For more information, see Section 1. Why am I using PAVTIDE ACCUHALER? in the full CMI. 2. WHAT SHOULD I KNOW BEFORE I USE PAVTIDE ACCUHALER? Do not use if you have ever had an allergic reaction to any medicine containing fluticasone propionate or salmeterol xinafoate, lactose monohydrate or milk proteins, or any of the ingredients listed at the end of the CMI. TALK TO YOUR DOCTOR IF YOU HAVE ANY OTHER MEDICAL CONDITIONS, TAKE ANY OTHER MEDICINES, OR ARE PREGNANT OR PLAN TO BECOME PREGNANT OR ARE BREASTFEEDING. For more information, see Section 2. What should I know before I use PAVTIDE ACCUHALER? in the full CMI. 3. WHAT IF I AM TAKING OTHER MEDICINES? Some medicines may interfere with PAVTIDE ACCUHALER and affect how it works. A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI. 4. HOW DO I USE PAVTIDE ACCUHALER? • Follow dosage directions given to you by your doctor or pharmacist and continue taking it for as long as your doctor tells you. • PAVTIDE ACCUHALER should be inhaled into your lungs through the mouth. More instructions can be found in Section 4. How do I use PAVTIDE ACCUHALER? in the full CMI. 5. WHAT SHOULD I KNOW WHILE USING PAVTIDE ACCUHALER? THINGS YOU SHOULD DO • Remind any doctor, dentist or pharmacist you visit that you are using PAVTIDE ACCUHALER. • If you are going to have surgery, tell the surgeon or anesthetist that you are taking this medicine. • Tell your doctor if you become, or are trying to become, pregnant. • Tell your doctor if you are using PAVTIDE ACCUHALER, i Read the complete document
1 AUSTRALIAN PRODUCT INFORMATION PAVTIDE (FLUTICASONE PROPIONATE/ SALMETEROL XINAFOATE) ACCUHALER AND MDI 1 NAME OF THE MEDICINE Fluticasone propionate/ salmeterol xinafoate 2 QUALITATIVE AND QUANTITATIVE COMPOSITION PAVTIDE ACCUHALER: Each a foil strip contains regularly placed blisters each containing 100, 250 or 500 micrograms of fluticasone propionate and 50 micrograms of salmeterol (as xinafoate). PAVTIDE metered dose inhaler (MDI): Each single actuation provides 50, 125 or 250 micrograms of fluticasone propionate and 25 micrograms of salmeterol (as xinafoate). LIST OF EXCIPIENTS WITH KNOWN EFFECT PAVTIDE ACCUHALER also contains the excipient lactose monohydrate (which contains milk protein) (see Section 4.3 CONTRAINDICATIONS). For the full list of excipients, see Section 6.1 LIST OF EXCIPIENTS. 3 PHARMACEUTICAL FORM PAVTIDE ACCUHALER: Powder for inhalation PAVTIDE MDI: Pressurised inhalation 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the regular treatment of asthma, where the use of a combination product is appropriate. This may include: • Patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids • Patients who are symptomatic on current inhaled corticosteroid therapy • Initiation of maintenance therapy in those patients with moderate persistent asthma not adequately controlled on ‘as needed’ reliever medication, and who have moderate/severe airway limitation and daily symptoms requiring reliever medication every day (see Section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical trials). For the symptomatic treatment of patients with severe COPD (FEV1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular 2 beta-2 agonist bronchodilator therapy. PAVTIDE is not indicated for the initiation of bronchodilator therapy in COPD. 4.2 DOSE AND METHOD OF ADMINISTRATION PAVTIDE ACCUHALER and MDI are for inhalation only. PAVTIDE ACCUHALER and MDI must be used regularly for optimum benefit, even when asymptomatic. Read the complete document